Distinguished in Common Variable Immune Deficiency

Dr. Patrick J. Ward

Hematology Oncology | Oncology | Hematology
Oncology Hematology Care Inc
4350 Malsbary Rd, 
Blue Ash, OH 
Accepting New Patients
Distinguished in Common Variable Immune Deficiency
Oncology Hematology Care Inc
4350 Malsbary Rd, 
Blue Ash, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Patrick Ward is a Hematologist Oncology specialist and an Oncologist in Blue Ash, Ohio. Dr. Ward is rated as a Distinguished provider by MediFind in the treatment of Common Variable Immune Deficiency. His top areas of expertise are Lung Cancer, Breast Cancer, Colorectal Cancer, Pleuropulmonary Blastoma, and Tissue Biopsy. Dr. Ward is currently accepting new patients.

His clinical research consists of co-authoring 34 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Oncology
Hematology
Licenses
Internal Medicine in OH
Hospital Affiliations
Mercy Health-Anderson Hospital
The Jewish Hospital-Mercy Health
Mercy Health - Clermont Hospital
Mercy Health Kings Mills Hospital LLC
Mercy Health - West Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
First Health
  • INSURANCE PLAN
  • MEDICARE PDP
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Health
  • HMO
  • PPO
Medical Mutual
  • HMO
  • PPO
Trustmark
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

ONCOLOGY HEMATOLOGY CARE INC
4350 Malsbary Rd, Blue Ash, OH 45242

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment
A Phase III Randomized Double-blind, Placebo Controlled Study of Alpelisib in Combination With Fulvestrant for Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment
Enrollment Status: Completed
Publish Date: February 13, 2025
Intervention Type: Drug
Study Drugs: Fulvestrant, Alpelisib
Study Phase: Phase 3
A Phase 1/2 Study of Galinpepimut-S in Combination With Pembrolizumab (MK 3475) in Patients With Selected Advanced Cancers
A Phase 1/2 Study of Galinpepimut-S in Combination With Pembrolizumab (MK 3475) in Patients With Selected Advanced Cancers
Enrollment Status: Completed
Publish Date: November 19, 2024
Intervention Type: Biological, Other
Study Drugs: Galinpepimut-S, Pembrolizumab
Study Phase: Phase 1/Phase 2
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma
Enrollment Status: Completed
Publish Date: August 14, 2023
Intervention Type: Drug
Study Drugs: tucatinib, capecitabine, trastuzumab
Study Phase: Phase 2
A Randomized Multicenter Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of Vaccination With Folate Receptor Alpha Peptides With GM-CSF in Patients With Triple Negative Breast Cancer Defined as Primary Tumor That is Her2-neu and Low (< 10%) ER/PR Nuclear Staining
A Randomized Multicenter Phase II Trial to Evaluate the Safety and Immunogenicity of Two Doses of Vaccination With Folate Receptor Alpha Peptides With GM-CSF in Patients With Triple Negative Breast Cancer Defined as Primary Tumor That is Her2-neu and Low (< 10%) ER/PR Nuclear Staining
Enrollment Status: Completed
Publish Date: July 19, 2021
Intervention Type: Biological, Drug
Study Drugs: FR? vaccine, Cyclophosphamide
Study Phase: Phase 2
A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer
A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: March 12, 2020
Intervention Type: Drug
Study Phase: Phase 1
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
Enrollment Status: Completed
Publish Date: March 08, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

34 Total Publications

Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trial.
Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trial.
Journal: Lung cancer (Amsterdam, Netherlands)
Published: March 25, 2025
Similar Doctors
Distinguished in Common Variable Immune Deficiency
Dr. Colleen M. Darnell
Hematology Oncology | Oncology | Hematology
Distinguished in Common Variable Immune Deficiency
Dr. Colleen M. Darnell
Hematology Oncology | Oncology | Hematology

St Elizabeth Medical Center, Inc

1 Medical Village Dr, 
Edgewood, KY 
 (18.2 miles away)
859-301-2237
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Colleen Darnell is a Hematologist Oncology specialist and an Oncologist in Edgewood, Kentucky. Dr. Darnell is rated as a Distinguished provider by MediFind in the treatment of Common Variable Immune Deficiency. Her top areas of expertise are Lung Cancer, Small Cell Lung Cancer (SCLC), Pleuropulmonary Blastoma, and Colorectal Cancer. Dr. Darnell is currently accepting new patients.

Distinguished in Common Variable Immune Deficiency
Dr. Mark E. Johns
Hematology Oncology | Oncology | Hematology
Distinguished in Common Variable Immune Deficiency
Dr. Mark E. Johns
Hematology Oncology | Oncology | Hematology

Oncology Hematology Care Inc

601 Ivy Gateway, Suite 1, 
Cincinnati, OH 
 (11.8 miles away)
513-751-2273
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Mark Johns is a Hematologist Oncology specialist and an Oncologist in Cincinnati, Ohio. Dr. Johns is rated as a Distinguished provider by MediFind in the treatment of Common Variable Immune Deficiency. His top areas of expertise are Paget Disease of the Breast, Breast Cancer, Pleuropulmonary Blastoma, Lung Cancer, and Bone Marrow Aspiration. Dr. Johns is currently accepting new patients.

Advanced in Common Variable Immune Deficiency
Dr. Ketan S. Shah
Hematology Oncology | Oncology | Hematology
Advanced in Common Variable Immune Deficiency
Dr. Ketan S. Shah
Hematology Oncology | Oncology | Hematology

Dayton Physicians LLC

3120 Governors Place Blvd, 
Kettering, OH 
 (33.7 miles away)
937-293-1622
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Ketan Shah is a Hematologist Oncology specialist and an Oncologist in Kettering, Ohio. Dr. Shah is rated as an Advanced provider by MediFind in the treatment of Common Variable Immune Deficiency. His top areas of expertise are Thrombocytopenia, Breast Cancer in Men, Myelodysplastic Syndrome (MDS), Pleuropulmonary Blastoma, and Bone Marrow Aspiration. Dr. Shah is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ward's expertise for a condition
ConditionClose
    View All 10 Distinguished Conditions
    View All 39 Advanced Conditions
    View All 140 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile